AU2006251429A1 - Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment - Google Patents

Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment Download PDF

Info

Publication number
AU2006251429A1
AU2006251429A1 AU2006251429A AU2006251429A AU2006251429A1 AU 2006251429 A1 AU2006251429 A1 AU 2006251429A1 AU 2006251429 A AU2006251429 A AU 2006251429A AU 2006251429 A AU2006251429 A AU 2006251429A AU 2006251429 A1 AU2006251429 A1 AU 2006251429A1
Authority
AU
Australia
Prior art keywords
compound
cancer
formula
combination
wortmannin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006251429A
Other languages
English (en)
Inventor
Ingo Bernard
Urban Scheuring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of AU2006251429A1 publication Critical patent/AU2006251429A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006251429A 2005-05-27 2006-05-13 Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment Abandoned AU2006251429A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05011477.6 2005-05-27
EP05011477 2005-05-27
PCT/EP2006/004524 WO2006125540A1 (en) 2005-05-27 2006-05-13 Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment

Publications (1)

Publication Number Publication Date
AU2006251429A1 true AU2006251429A1 (en) 2006-11-30

Family

ID=36636325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006251429A Abandoned AU2006251429A1 (en) 2005-05-27 2006-05-13 Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment

Country Status (11)

Country Link
EP (1) EP1888067A1 (ru)
JP (1) JP2008542214A (ru)
KR (1) KR20080018908A (ru)
CN (1) CN101257903A (ru)
AU (1) AU2006251429A1 (ru)
BR (1) BRPI0610048A2 (ru)
CA (1) CA2609389A1 (ru)
IL (1) IL187508A0 (ru)
MX (1) MX2007014726A (ru)
RU (1) RU2007148266A (ru)
WO (1) WO2006125540A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
JP5304241B2 (ja) 2005-03-07 2013-10-02 バイエル・ヘルスケア・エルエルシー 癌の処置用のオメガ−カルボキシアリール置換ジフェニルウレアを含む医薬組成物
US20100129321A1 (en) * 2005-12-15 2010-05-27 Bayer Healthcare Llc Diaryl urea for treating virus infections
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100173954A1 (en) * 2007-01-19 2010-07-08 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
US8680124B2 (en) 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP2011525503A (ja) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全を処置するためのジアリールウレア
US8791131B2 (en) * 2008-09-30 2014-07-29 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
CA2763589A1 (en) * 2009-05-28 2010-12-02 President And Fellows Of Harvard College N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
CN102775385A (zh) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用
CN102643229A (zh) * 2012-01-17 2012-08-22 湖南有色凯铂生物药业有限公司 N-((4-氯-3-三氟甲基)苯基)-n’-((2-氟-4-(2-氨基甲酰基)-4-吡啶基氧)苯基)脲及其作为抗癌药物的应用
CN102885814A (zh) * 2012-01-17 2013-01-23 湖南有色凯铂生物药业有限公司 一种化合物及其作为抗癌药物的应用
CN102940884B (zh) * 2012-11-19 2013-11-06 上海市肿瘤研究所 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用
US10420761B2 (en) 2013-03-15 2019-09-24 University Of Florida Research Foundation, Inc. Allosteric inhibitors of thymidylate synthase
KR102016822B1 (ko) * 2014-12-17 2019-08-30 화이자 인코포레이티드 정맥내 투여용 pi3k/mtor-억제제의 제형
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
CN104906086A (zh) * 2015-06-24 2015-09-16 安徽四正医药科技有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物用于治疗肾小球肾炎药物的应用
WO2016209688A1 (en) 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
KR102544163B1 (ko) * 2022-08-10 2023-06-16 주식회사 하이밸 소음저감형 유량 및 압력 조절용 감압밸브
CN115804844B (zh) * 2022-09-26 2024-05-10 郑州大学 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297490T3 (es) * 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.

Also Published As

Publication number Publication date
EP1888067A1 (en) 2008-02-20
RU2007148266A (ru) 2009-07-10
IL187508A0 (en) 2008-06-05
WO2006125540A1 (en) 2006-11-30
MX2007014726A (es) 2008-02-14
CA2609389A1 (en) 2006-11-30
CN101257903A (zh) 2008-09-03
KR20080018908A (ko) 2008-02-28
BRPI0610048A2 (pt) 2010-05-25
JP2008542214A (ja) 2008-11-27

Similar Documents

Publication Publication Date Title
US20090192127A1 (en) Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
AU2006251429A1 (en) Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment
US20090306020A1 (en) Combination therapy comprising diaryl ureas for treating diseases
JP5978293B2 (ja) Ｎａｍｐｔを阻害するための新規な化合物および組成物
JP5735931B2 (ja) ストレス活性化蛋白質キナーゼ系をモジュレートするためのピリドン誘導体
JP6342392B2 (ja) 置換型ピラゾロン化合物及び使用方法
JP6542808B2 (ja) ラパマイシン誘導体、並びにその調製方法、医薬組成物及び使用
CA2734415A1 (en) Picolinamide derivatives as kinase inhibitors
KR20140097402A (ko) 항암 및 항증식 활성을 나타내는 피리돈 아미드 및 유사체
PL220952B1 (pl) 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
WO2011057145A2 (en) Imidazo[1,2-a] pyridine compounds, synthesis thereof, and methods of using same
AU2015313782A1 (en) Compounds and compositions as RAF kinase inhibitors
US20130310374A1 (en) Substituted Imidazoquinoline Derivatives
CN101778825A (zh) 适用作詹纳斯激酶抑制剂的n-杂环类化合物
EP3628669A1 (en) Novel compounds as nadph oxidase inhibitors
KR102668390B1 (ko) 신규한 pan-RAF 키나아제 저해제 및 이의 용도
JP4365586B2 (ja) 血管形成阻害活性を有するフタラジン誘導体
CN101180055A (zh) 用于治疗疾病的包含二芳基脲的组合治疗
TW202428252A (zh) 類Cdc激酶之雜環抑制劑
JP2022506289A (ja) インダゾールキナーゼ阻害剤及びその使用
CA3154278A1 (en) Phosphodiesterase inhibitors
TW201406377A (zh) 抗癌劑之抗性克服劑

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period